jbcrg.jp
JBCRG概要 | 一般社団法人 JBCRG
http://www.jbcrg.jp/about
当法人は わが国及び多国間における乳がんの臨床試験及び基礎的研究を計画、推進すること、 さらに乳がんの医療に関する国内外の情報の調査研究と普及啓発を行い、乳がんに対する診療技術の向上を促進 振興するとともに、 関連団体との連絡、提携を図る事業を行い、もって乳がんに対する治療成績の向上を通して、公共の福祉に貢献することを目的としています。 また、JBCRGは、国際的な乳がん研究グループであるBreast International Group (BIG のメンバーです。 国立病院機構 四国がんセンター 乳腺 内分泌外科. 国立がん研究センター 中央病院 乳腺 腫瘍内科. 昭和大学 医学部 外科学講座 乳腺外科学. 国立病院機構 大阪医療センター 外科 乳腺外科. 熊本大学大学院 生命科学研究部 乳腺 内分泌外科学講座. 国立病院機構 四国がんセンター 乳腺 内分泌外科. 東邦大学 医学部医学科 社会医学講座 医療統計学. 筑波大学 医学医療系 臨床医学域 乳腺内分泌外科学. 横浜市立大学附属 市民総合医療センター 臨床統計学 疫学. 筑波大学 医学医療系 臨床医学域 乳腺内分泌外科学.
jbcrg.jp
広報・ＰＲ | 一般社団法人 JBCRG
http://www.jbcrg.jp/press
18 10 19 00のNHK 首都圏ネットワーク および同日20 45 21 00の 首都圏ニュース845 再放送 に取り上げられました。 TEL 03-6264-8873 FAX 03-6264-8875.
jbcrg.jp
Japan Breast Cancer Research Group
http://www.jbcrg.jp/en
Cancer Institute Hospital, Breast Oncology Center. JBCRG was founded to activate the breast cancer clinical trials and to provide the information from Japan to the world, therefore improving the treatment outcomes and patients' quality of life. Our research projects are developing thanks to the participation of many patients along with the generous support from corporations and organizations. Senior Director, Founder of JBCRG. JBCRG-04(CREATE-X)presented at SABCS 2015 link available. 16 December, 2015).
jbcrg.jp
学会発表 | 一般社団法人 JBCRG
http://www.jbcrg.jp/conference
Efficacy study of sequential therapy with anthracycline, taxane, and eribulin in patients with HER2-negative locally advanced breast cancer (JBCRG-17). Naoto Kondo, Yoshinori Ito, Ippei Fukada, Shoichiro Ohtani, Masaya Hattori, Eriko Tokunaga, Nobuki Matsunami, Kohjiro Mashino, Taijiro Kosaka, Masahiko Tanabe, Daisuke Yotsumoto, Kosho Yamanouchi, Masataka Sawaki, Masahiro Kashiwaba, Hidetaka Kawabata, Katsumasa Kuroi, Satoshi Morita, Shinji Ohno, Masakazu Toi, Norikazu Masuda. Kosuke Kawaguchi, Eiji Suzu...
supremo-trial.com
SUPREMO | Selective Use of Postoperative Radiotherapy After Mastectomy
http://www.supremo-trial.com/participating-sites.asp
SUPREMO is open to recruitment in over 100 hospitals in the UK. The EORTC has almost 30 sites open across Europe, including France, Belgium, The Netherlands, Poland, Israel, Germany, Spain and Turkey. There are 21 international sites open to recruitment including China, Japan, Singapore, Australia and Ireland. For a complete list of centres please contact the team listed under ' Contact Us. Total number of patients recruited=1688. Number or particicpating sites. Number of patients recruited.
supremo-trial.com
SUPREMO | Selective Use of Postoperative Radiotherapy After Mastectomy
http://www.supremo-trial.com/events.asp
We recently conducted two teleconferences with sites to reiterate the Adverse Event Reporting and Informed Consent procedures. It also gave sites an opportunity to ask any questions they had regarding Protocol Version 29. We have put together a list of the questions raised during both teleconferences as well as the presentation both which can be accessed using the links below. Supremo - Questions Raised. SUPREMO Telecoference with all sites. 0169; SUPREMO 2010. Scottish Clinical Trials Research Unit.
supremo-trial.com
SUPREMO | Selective Use of Postoperative Radiotherapy After Mastectomy
http://www.supremo-trial.com/patients.asp
This is the patients area of the website. This is for patients who have been diagnosed with breast cancer. Here you will find information about taking part in the Supremo breast cancer trial and the three trial substudies. There are also links to more information about breast cancer and about radiotherapy. In the section you can find:. Summary of the Trial. What happens if I decide to take part? What happens if I decide not to take part? What does radiotherapy involve? Quality of Life ( QoL).
ceeog.org
Collaboration
http://www.ceeog.org/collaboration.html
Last Updated on Wednesday, 10 October 2012 22:27. Published on Monday, 08 October 2012 10:41. Breast International Group (BIG) http:/ www.breastinternationalgroup.org/. Hoosier Oncology Group, Indianapolis, USA http:/ www.hoosieroncologygroup.org/. Monogram Biosciences, San Francisco http:/ www.monogrambio.com/. GlaxoSmithKline http:/ www.gsk.com.pl/. Celon Pharma http:/ www.celonpharma.com/pl/careers.php. Roche Polska Sp. Z o.o. http:/ www.roche.pl/portal/eipf/poland/portal/pl. 80-211 Gdańsk, Poland.
supremo-trial.com
SUPREMO | Selective Use of Postoperative Radiotherapy After Mastectomy
http://www.supremo-trial.com/investigators.asp
Thank you for taking part in the Supremo breast cancer trial. In this area of the website you will find more information about the trial, including the trial protocol, information about the substudies, and a separate area on pathology grading. Collaborating Breast Cancer Trial Groups Summary Of Trial. Neoadjuvant eligability flowchart (version 29). Non-Neoadjuvant eligability flowchart (version 29). Explaining SUPREMO to patients - notes for clinicians. Quality of Life ( QoL). 0169; SUPREMO 2010.
supremo-trial.com
SUPREMO | Selective Use of Postoperative Radiotherapy After Mastectomy
http://www.supremo-trial.com/useful-links.asp
TRANS-SUPREMO and Cardiac Substudy laboratory manuals. TRANS-SUPREMO and Cardiac Substudy laboratory manuals. Are available for download here. Version 6 - April 2016, (329k). Download the latest version of Adobe Reader. If you have problems viewing this document. Is available for download here. Version 5 - April 2016, (250k). Download the latest version of Adobe Reader. If you have problems viewing this document. TRANS-SUPREMO laboratory manual - EORTC. TRANS-SUPREMO laboratory manual EORTC.
SOCIAL ENGAGEMENT